Forecast to Publish a Notice of Funding Opportunity for Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed)
ID: 359724Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359724
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Small Business Transition Grant aimed at early-career scientists, specifically under the R41/R42 activity code, with a focus on supporting their transition to entrepreneurship. This initiative seeks to address the challenges of identifying the right expertise and securing funding for early-stage technology development, thereby facilitating the transfer of innovative technologies from academic laboratories to small businesses. The program is crucial for fostering technological innovation in the U.S. and is expected to award approximately 20 grants, with applications anticipated to open in Fall 2025. For further inquiries, interested parties can contact Dr. Saroj Regmi at saroj.regmi@nih.gov or call 240-276-7289.

    Point(s) of Contact
    Saroj Regmi, Ph.D. National Cancer Institute (NCI)
    (240) 276-7289
    saroj.regmi@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the "Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)" to support early-career scientists in their transition to entrepreneurship. This grant aims to facilitate the development of small business concerns (SBCs) by employing researchers as Program Directors/Principal Investigators (PDs/PIs), providing them with essential entrepreneurial training, mentorship, and a structured framework for developing commercially viable biomedical technologies. The program is particularly focused on enhancing the entrepreneurial skills of scientists with strong technical expertise but limited experience in entrepreneurship, thereby aligning with NIH's mission to improve health. Interested applicants must be U.S.-based small businesses, and the application process will commence in September 2024, with a closing date of April 5, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-133.html.
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required) to support early-career scientists transitioning into entrepreneurial roles within small businesses. This funding opportunity aims to facilitate the career development of investigators by providing entrepreneurial training, mentorship, and support for research and development projects that align with NIH's mission to improve health. Eligible small business concerns (SBCs) can apply for Phase I and Fast-Track grants, with funding amounts typically reaching $306,872 for Phase I and $2,045,816 for Phase II awards. Applications will be accepted starting August 5, 2024, with a closing date of April 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-134.html.
    Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed) to support early-career scientists transitioning into entrepreneurship. This funding opportunity aims to facilitate the development of promising technologies by small business concerns (SBCs) while providing mentorship and entrepreneurial training for Program Directors/Principal Investigators (PDs/PIs) who are new to research entrepreneurship. The initiative is designed to enhance the biomedical workforce by coupling scientific expertise with essential business skills, ultimately contributing to public health advancements. Applications are invited for SBIR Phase I and Fast-Track grants, with deadlines ranging from September 2024 to April 2027. For more information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-131.html.
    Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the "Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required)" to support early-career scientists transitioning into entrepreneurship. This funding opportunity aims to facilitate the career development of investigators by providing grants that support research and development activities, alongside essential entrepreneurial training and mentorship. The program is specifically designed for U.S. small business concerns, with a focus on fostering innovation and enhancing public health, particularly from diverse and historically underrepresented groups. Interested applicants must submit their proposals by April 5, 2027, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Trailblazer Award for New and Early-Stage Investigators (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Trailblazer Award aimed at New and Early-Stage Investigators, with a focus on integrating engineering and physical sciences with life and biomedical sciences. This grant opportunity, utilizing the R21 activity code, encourages innovative research projects that may be exploratory, developmental, or high-risk high-impact, and aims to foster collaborations that open new areas of biomedical investigation. Interested applicants, particularly those with expertise in engineering and quantitative sciences, should prepare to submit their applications once the NOFO is officially released, with an estimated synopsis post date of November 21, 2025, and a projected award date of October 1, 2026. For further inquiries, potential applicants can contact Randy King at the National Institute of Biomedical Imaging and Bioengineering via email at Randy.King@nih.gov or by phone at 301-451-0707.
    Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for Small Business Innovation Research (SBIR) Phase IIB Bridge Awards aimed at accelerating the development of cancer-relevant technologies toward commercialization. This funding opportunity is designed for small business concerns (SBCs) that have previously received SBIR or STTR Phase II awards from any Federal agency and are seeking additional funding to transition their projects to the commercialization stage. The initiative emphasizes the importance of fostering partnerships between awardees and third-party investors to support the capital-intensive steps necessary for bringing new products and services to market. While applications are not currently being solicited, the NOFO is expected to be published in Summer 2025, with an anticipated application due date in Fall 2025. For further inquiries, interested parties can contact Jonathan Franca-Koh, Ph.D., M.B.A. at 240-618-0984 or via email at francakohjc@mail.nih.gov.
    NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed) aimed at encouraging United States small business concerns (SBCs) to engage in research and development projects aligned with NIH's mission. Eligible applicants, defined as SBCs by the Small Business Administration, are invited to prepare for future submissions of Phase I, Phase II, Fast-Track, and Phase IIB grant applications, although applications are not currently being solicited. This funding opportunity is significant for fostering innovative health-related research and collaboration among small businesses and NIH institutes. Interested parties can reach out to the NIH SEED Office of Extramural Research at SEEDinfo@nih.gov or by phone at 301-827-8595 for further information, with the estimated synopsis posting date set for October 1, 2025, and a projected award date of June 1, 2026.
    Forecast for Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the R21 grant aimed at enhancing clinical trial readiness for rare diseases, disorders, and syndromes. This initiative seeks to support research projects that address critical needs in the field, such as the development of biomarkers and clinical outcome measures, which are essential for facilitating the transition of therapeutics and diagnostics into clinical trials. The opportunity is particularly significant as it aims to improve the success rates of clinical trials for rare diseases, which often face unique challenges. Interested small businesses are encouraged to begin forming collaborations and developing proposals, with the estimated synopsis posting date set for November 14, 2025, and applications expected to be accepted until February 16, 2026. For further inquiries, potential applicants can contact Dr. Alice Chen Grady at alice.chen2@nih.gov or by phone at 301-827-2015.
    Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for the R61/R33 grant program, aimed at supporting investigator-initiated single-site clinical trials. This initiative encourages applications that focus on various types of clinical trials, including efficacy, comparative effectiveness, and implementation research, particularly those employing innovative trial designs such as adaptive and Bayesian methods. The trials must align with the research mission of the National Heart, Lung, and Blood Institute (NHLBI) and adhere to the NIH definition of a clinical trial. Interested small businesses are advised to begin developing collaborative projects in anticipation of the application period, which is expected to open following the estimated synopsis post date of July 11, 2025, with applications due by October 13, 2025. For further inquiries, potential applicants can contact Dr. Yves Rosenberg at rosenbey@nhlbi.nih.gov or by phone at 301-435-1292.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.